CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$45.06 USD
+0.60 (1.35%)
Updated Mar 21, 2023 04:00 PM ET
After-Market: $45.09 +0.03 (0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About PE Ratio (TTM)
CRISPR Therapeutics AG has a trailing-twelve-months P/E of 22.55X compared to the Medical - Biomedical and Genetics industry's P/E of 21.00X.
Price to Earnings Ratio or P/E is price / earnings. It is the most commonly used metric for determining a company's value relative to its earnings. In this example, we are using the actual earnings (EPS) for the trailing twelve months (or TTM). A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its trailing twelve months earnings. In general, a lower number or multiple is usually considered better than a higher one.
CRSP 45.06 +0.60(1.35%)
Will CRSP be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
No Record found.Other News for CRSP
FDA to back accelerated approval pathway for gene therapies
Crispr Therapeutics initiated with a Market Perform at Bernstein
Crispr Therapeutics price target lowered to $55 from $63 at Citi
3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time
Crispr Therapeutics initiated with a Buy at Bryan Garnier